These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35993470)

  • 1. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications.
    Gupta SK; Tripathi PK
    Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
    Hamada Y; Nakamura J
    Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q; Liu Q; Ouyang D
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential use of aldose reductase inhibitors to prevent diabetic complications.
    Zenon GJ; Abobo CV; Carter BL; Ball DW
    Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
    Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
    Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.
    Hu X; Li S; Yang G; Liu H; Boden G; Li L
    PLoS One; 2014; 9(2):e87096. PubMed ID: 24533052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
    Gabbay KH
    Curr Diab Rep; 2004 Dec; 4(6):405-8. PubMed ID: 15539002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
    Kovacikova L; Prnova MS; Majekova M; Bohac A; Karasu C; Stefek M
    Molecules; 2021 May; 26(10):. PubMed ID: 34066081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase, still a compelling target for diabetic neuropathy.
    Oates PJ
    Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
    Kador PF; Wyman M; Oates PJ
    Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong inhibition of the polyol pathway diverts glucose flux to protein glycation leading to rapid establishment of secondary complications in diabetes mellitus.
    Jagdale AD; Bavkar LN; More TA; Joglekar MM; Arvindekar AU
    J Diabetes Complications; 2016 Apr; 30(3):398-405. PubMed ID: 26896333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of aldose reductase inhibitors in diabetic complications: recent trends.
    Kaul CL; Ramarao P
    Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
    J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enzymological Studies on the Mechanisms of Pathogenesis of Diabetic Complications].
    Tanimoto T
    Yakugaku Zasshi; 2018; 138(3):405-415. PubMed ID: 29503433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
    van Gerven JM; Tjon-A-Tsien AM
    Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.